INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)
TURMERIC OLEORESIN
NTP Experiment-Test: 05084-01 Report: PEIRPT05
Study Type: CHRONIC Date: 09/10/94
Route: DOSED FEED Time: 21:38:55
Facility: TSI Mason Research
Chemical CAS #: 458-37-7
Lock Date: None
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05084-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TURMERIC OLEORESIN Date: 09/10/94
Route: DOSED FEED Time: 21:38:55
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE 0 PPM 2,000PPM 10,000 50,000
FEMALE FEMALE PPM FEM PPM FEM
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 60 60 60 60
Scheduled Sacrifice 10 10 10 9
Early Deaths
Dead 3 1 3 2
Moribund 14 22 19 15
Survivors
Terminal Sacrifice 32 26 28 34
Dead 1 1
Animals Examined Microscopically 60 60 60 60
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Large, Cecum (60) (60) (60) (60)
Intestine Large, Colon (60) (60) (60) (59)
Intestine Small, Duodenum (60) (60) (60) (60)
Intestine Small, Ileum (60) (60) (59) (60)
Intestine Small, Jejunum (60) (59) (60) (60)
Liver (60) (52) (54) (60)
Hepatocellular Adenoma 1 (2%)
Mesentery (5) (4) (4) (2)
Leiomyoma 1 (25%)
Sarcoma 1 (25%)
Pancreas (60) (50) (50) (59)
Pharynx (1) (1)
Palate, Squamous Cell Carcinoma 1 (100%) 1 (100%)
Salivary Glands (60) (50) (50) (60)
Parotid Gland, Schwannoma Malignant 1 (2%)
Submandibular Gland, Schwannoma Malignant 1 (2%)
Stomach, Forestomach (60) (60) (59) (60)
Squamous Cell Papilloma 1 (2%) 1 (2%) 1 (2%)
Stomach, Glandular (60) (60) (59) (60)
Tongue (1) (1)
Squamous Cell Papilloma 1 (100%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (60) (50) (50) (60)
____________________________________________________________________________________________________________________________________
Page 2
NTP Experiment-Test: 05084-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TURMERIC OLEORESIN Date: 09/10/94
Route: DOSED FEED Time: 21:38:55
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE 0 PPM 2,000PPM 10,000 50,000
FEMALE FEMALE PPM FEM PPM FEM
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland, Cortex (60) (50) (51) (59)
Adenoma 3 (6%) 1 (2%)
Adrenal Gland, Medulla (60) (49) (50) (59)
Pheochromocytoma Benign 3 (5%) 2 (4%) 2 (3%)
Islets, Pancreatic (59) (50) (50) (59)
Adenoma 2 (3%) 1 (2%)
Carcinoma 1 (2%) 1 (2%)
Parathyroid Gland (55) (47) (49) (55)
Pituitary Gland (60) (49) (52) (60)
Pars Distalis, Adenoma 25 (42%) 25 (51%) 24 (46%) 24 (40%)
Pars Distalis, Adenoma, Multiple 3 (5%) 2 (4%) 1 (2%) 1 (2%)
Pars Distalis, Carcinoma 2 (3%) 1 (2%)
Thyroid Gland (60) (51) (52) (60)
C-Cell, Adenoma 6 (10%) 2 (4%) 3 (6%) 3 (5%)
C-Cell, Carcinoma 2 (3%) 1 (2%)
Follicular Cell, Adenocarcinoma 1 (2%)
Follicular Cell, Adenoma 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Tissue NOS (1) (1) (2)
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Clitoral Gland (60) (51) (49) (58)
Adenocarcinoma 1 (2%) 4 (8%)
Adenoma 7 (12%) 13 (25%) 15 (31%) 17 (29%)
Adenoma, Multiple 1 (2%)
Ovary (60) (51) (51) (60)
Granulosa Cell Tumor Malignant 1 (2%)
Granulosa Cell Tumor Benign 2 (3%)
Uterus (60) (50) (50) (60)
Leiomyosarcoma 1 (2%)
Polyp Stromal 10 (17%) 10 (20%) 11 (22%) 9 (15%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Blood (1)
Bone Marrow (60) (60) (52) (60)
Lymph Node (60) (60) (56) (60)
Lymph Node, Mandibular (4) (9) (6) (7)
Lymph Node, Mesenteric (60) (60) (56) (60)
Spleen (60) (50) (51) (60)
Page 3
NTP Experiment-Test: 05084-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TURMERIC OLEORESIN Date: 09/10/94
Route: DOSED FEED Time: 21:38:55
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE 0 PPM 2,000PPM 10,000 50,000
FEMALE FEMALE PPM FEM PPM FEM
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - cont
Thymus (51) (48) (45) (50)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (60) (49) (49) (59)
Adenocarcinoma 2 (3%) 1 (2%) 2 (4%)
Adenoma 1 (2%)
Fibroadenoma 7 (12%) 18 (37%) 17 (35%) 14 (24%)
Fibroadenoma, Multiple 6 (10%) 4 (8%) 2 (4%) 2 (3%)
Skin (58) (50) (51) (59)
Squamous Cell Papilloma 1 (2%)
Subcutaneous Tissue, Sarcoma 1 (2%)
Subcutaneous Tissue, Schwannoma Malignant 2 (4%) 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
None
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (60) (50) (50) (60)
Astrocytoma Malignant 1 (2%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (60) (52) (52) (60)
Alveolar/Bronchiolar Adenoma 1 (2%) 2 (4%) 1 (2%)
Alveolar/Bronchiolar Carcinoma 1 (2%)
Carcinoma, Metastatic, Pituitary Gland 1 (2%)
Sarcoma, Metastatic, Mesentery 1 (2%)
Squamous Cell Carcinoma, Metastatic,
Uncertain Primary Site 1 (2%)
Nose (59) (56) (52) (60)
Squamous Cell Carcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Eye (9) (10) (7) (13)
Zymbal's Gland (2) (1)
Adenocarcinoma 1 (50%)
Carcinoma 1 (50%) 1 (100%)
____________________________________________________________________________________________________________________________________
Page 4
NTP Experiment-Test: 05084-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TURMERIC OLEORESIN Date: 09/10/94
Route: DOSED FEED Time: 21:38:55
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE 0 PPM 2,000PPM 10,000 50,000
FEMALE FEMALE PPM FEM PPM FEM
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (60) (51) (49) (60)
Urinary Bladder (60) (48) (49) (60)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(60) *(60) *(60) *(60)
Leukemia Mononuclear 15 (25%) 19 (32%) 18 (30%) 21 (35%)
Lymphoma Malignant Mixed 1 (2%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 5
NTP Experiment-Test: 05084-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TURMERIC OLEORESIN Date: 09/10/94
Route: DOSED FEED Time: 21:38:55
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE 0 PPM 2,000PPM 10,000 50,000
FEMALE FEMALE PPM FEM PPM FEM
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 53 50 49 49
Total Primary Neoplasms 105 106 110 100
Total Animals with Benign Neoplasms 46 47 44 44
Total Benign Neoplasms 76 75 84 76
Total Animals with Malignant Neoplasms 25 25 24 24
Total Malignant Neoplasms 29 31 26 24
Total Animals with Metastatic Neoplasms 1 1 1
Total Metastatic Neoplasm 1 1 1
Total Animals with Malignant Neoplasms 1
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 6
NTP Experiment-Test: 05084-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TURMERIC OLEORESIN Date: 09/10/94
Route: DOSED FEED Time: 21:38:55
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE 0 PPM 2,000PPM 10,000 50,000
MALE MALE PPM MALE PPM MALE
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 60 60 60 60
Scheduled Sacrifice 10 10 10 9
Early Deaths
Moribund 26 29 32 28
Dead 6 4 3 6
Survivors
Terminal Sacrifice 18 17 15 17
Animals Examined Microscopically 60 60 60 60
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Esophagus (59) (49) (49) (58)
Intestine Large, Cecum (60) (59) (60) (60)
Intestine Large, Colon (59) (60) (59) (58)
Adenocarcinoma 1 (2%)
Intestine Small, Duodenum (60) (60) (59) (60)
Intestine Small, Ileum (59) (60) (59) (60)
Intestine Small, Jejunum (60) (60) (59) (58)
Sarcoma 1 (2%)
Liver (60) (57) (56) (60)
Hepatocellular Carcinoma 1 (2%) 1 (2%) 1 (2%)
Hepatocellular Adenoma 1 (2%) 3 (5%) 2 (3%)
Hepatocellular Adenoma, Multiple 1 (2%) 1 (2%)
Histiocytic Sarcoma 1 (2%)
Mesentery (9) (3) (8) (7)
Liposarcoma 1 (13%)
Pancreas (58) (50) (50) (59)
Mixed Tumor Benign 1 (2%)
Salivary Glands (59) (49) (50) (59)
Stomach, Forestomach (59) (60) (53) (60)
Squamous Cell Papilloma 1 (2%)
Stomach, Glandular (60) (60) (60) (58)
Tongue (1) (1) (3)
Squamous Cell Papilloma 1 (33%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (60) (50) (50) (60)
Schwannoma Benign 1 (2%)
____________________________________________________________________________________________________________________________________
Page 7
NTP Experiment-Test: 05084-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TURMERIC OLEORESIN Date: 09/10/94
Route: DOSED FEED Time: 21:38:55
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE 0 PPM 2,000PPM 10,000 50,000
MALE MALE PPM MALE PPM MALE
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland, Cortex (60) (50) (50) (60)
Adenoma 1 (2%) 1 (2%)
Adrenal Gland, Medulla (57) (50) (51) (59)
Pheochromocytoma Malignant 1 (2%) 2 (4%) 1 (2%)
Pheochromocytoma Benign 9 (16%) 15 (30%) 13 (25%) 6 (10%)
Pheochromocytoma Benign, Multiple 5 (9%) 5 (10%) 5 (10%) 3 (5%)
Islets, Pancreatic (57) (50) (48) (58)
Adenoma 2 (4%) 1 (2%) 1 (2%) 3 (5%)
Carcinoma 1 (2%)
Parathyroid Gland (56) (47) (49) (55)
Adenoma 1 (2%) 1 (2%) 1 (2%)
Pituitary Gland (60) (51) (50) (58)
Pars Distalis, Adenoma 25 (42%) 16 (31%) 15 (30%) 12 (21%)
Pars Distalis, Adenoma, Multiple 1 (2%) 2 (4%) 2 (4%) 2 (3%)
Pars Intermedia, Adenoma 1 (2%)
Pars Nervosa, Adenoma 1 (2%)
Pars Nervosa, Craniopharyngioma 1 (2%)
Thyroid Gland (59) (50) (51) (60)
Carcinoma 1 (2%)
Bilateral, C-Cell, Adenoma 1 (2%)
C-Cell, Adenoma 4 (7%) 7 (14%) 5 (10%) 6 (10%)
C-Cell, Carcinoma 2 (3%)
Follicular Cell, Adenocarcinoma 1 (2%)
Follicular Cell, Adenoma 1 (2%) 2 (4%) 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Tissue NOS (1)
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Coagulating Gland (10) (2) (2) (9)
Epididymis (59) (50) (50) (59)
Preputial Gland (57) (51) (50) (60)
Adenocarcinoma 2 (4%) 2 (4%) 1 (2%) 1 (2%)
Adenoma 2 (4%) 5 (10%) 2 (4%) 3 (5%)
Bilateral, Adenoma 1 (2%)
Prostate (60) (50) (50) (60)
Seminal Vesicle (60) (50) (51) (59)
Testes (60) (53) (54) (60)
Bilateral, Interstitial Cell, Adenoma 31 (52%) 39 (74%) 34 (63%) 34 (57%)
Interstitial Cell, Adenoma 9 (15%) 8 (15%) 10 (19%) 9 (15%)
____________________________________________________________________________________________________________________________________
Page 8
NTP Experiment-Test: 05084-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TURMERIC OLEORESIN Date: 09/10/94
Route: DOSED FEED Time: 21:38:55
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE 0 PPM 2,000PPM 10,000 50,000
MALE MALE PPM MALE PPM MALE
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (60) (50) (49) (60)
Sternal, Histiocytic Sarcoma 1 (2%)
Lymph Node (59) (60) (60) (60)
Lymph Node, Mandibular (22) (15) (22) (17)
Squamous Cell Carcinoma, Metastatic 1 (5%)
Lymph Node, Mesenteric (59) (60) (60) (60)
Spleen (60) (52) (50) (59)
Thymus (50) (48) (45) (52)
Thymoma Benign 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (47) (39) (40) (50)
Adenocarcinoma 1 (3%)
Adenoma, Multiple 1 (2%)
Fibroadenoma 1 (3%) 1 (2%)
Skin (60) (51) (53) (60)
Basal Cell Adenoma 1 (2%)
Fibroma 1 (2%)
Fibrosarcoma 1 (2%)
Keratoacanthoma 3 (6%)
Squamous Cell Carcinoma 1 (2%)
Squamous Cell Papilloma 3 (5%) 2 (4%) 1 (2%)
Squamous Cell Papilloma, Multiple 1 (2%)
Sebaceous Gland, Adenoma 1 (2%)
Subcutaneous Tissue, Fibroma 2 (3%) 1 (2%) 1 (2%) 3 (5%)
Subcutaneous Tissue, Fibroma, Multiple 1 (2%)
Subcutaneous Tissue, Fibrosarcoma 1 (2%)
Subcutaneous Tissue, Hemangioma 1 (2%)
Subcutaneous Tissue, Lipoma 1 (2%) 1 (2%)
Subcutaneous Tissue, Sarcoma 1 (2%) 1 (2%) 1 (2%)
Subcutaneous Tissue, Schwannoma Malignant 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Skeletal Muscle (1) (1)
Rhabdomyosarcoma 1 (100%)
____________________________________________________________________________________________________________________________________
Page 9
NTP Experiment-Test: 05084-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TURMERIC OLEORESIN Date: 09/10/94
Route: DOSED FEED Time: 21:38:55
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE 0 PPM 2,000PPM 10,000 50,000
MALE MALE PPM MALE PPM MALE
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (60) (50) (50) (60)
Astrocytoma Malignant 1 (2%) 1 (2%)
Glioma Malignant 1 (2%)
Meninges, Granular Cell Tumor Benign 1 (2%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (59) (57) (57) (60)
Adenocarcinoma, Metastatic, Thyroid Gland 1 (2%)
Alveolar/Bronchiolar Adenoma 2 (3%) 2 (4%) 5 (9%) 2 (3%)
Alveolar/Bronchiolar Carcinoma 1 (2%) 1 (2%)
Sarcoma, Metastatic, Skin 1 (2%)
Squamous Cell Carcinoma 1 (2%)
Mediastinum, Alveolar/Bronchiolar Carcinoma,
Metastatic, Lung 1 (2%)
Nose (60) (50) (50) (59)
Chondroma 1 (2%)
Squamous Cell Carcinoma 1 (2%)
Respiratory Epithelium, Adenoma 1 (2%)
Trachea (60) (50) (50) (60)
Adenocarcinoma, Metastatic, Thyroid Gland 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Ear (1) (3)
Pinna, Schwannoma Malignant 1 (33%)
Eye (15) (5) (7) (9)
Lids, Fibroma 1 (14%)
Zymbal's Gland (1) (1)
Adenocarcinoma 1 (100%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (60) (52) (50) (60)
Renal Tubule, Adenoma 1 (2%)
Urinary Bladder (59) (50) (50) (59)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(60) *(60) *(60) *(60)
Histiocytic Sarcoma 1 (2%)
Leukemia Mononuclear 27 (45%) 29 (48%) 35 (58%) 23 (38%)
* Number of animals with any tissue examined microscopically
Page 10
NTP Experiment-Test: 05084-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TURMERIC OLEORESIN Date: 09/10/94
Route: DOSED FEED Time: 21:38:55
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE 0 PPM 2,000PPM 10,000 50,000
MALE MALE PPM MALE PPM MALE
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS - cont
Multiple Organs *(60) *(60) *(60) *(60)
Mesothelioma Benign 1 (2%)
Mesothelioma Malignant 2 (3%) 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
Page 11
NTP Experiment-Test: 05084-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TURMERIC OLEORESIN Date: 09/10/94
Route: DOSED FEED Time: 21:38:55
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE 0 PPM 2,000PPM 10,000 50,000
MALE MALE PPM MALE PPM MALE
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 56 55 55 49
Total Primary Neoplasms 143 153 160 125
Total Animals with Benign Neoplasms 54 53 53 48
Total Benign Neoplasms 104 113 111 94
Total Animals with Malignant Neoplasms 34 36 40 26
Total Malignant Neoplasms 39 40 49 31
Total Animals with Metastatic Neoplasms 2 2 1
Total Metastatic Neoplasm 2 3 1
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 12
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------